|
|
|
|
LEADER |
01000caa a22002652 4500 |
001 |
WHO006497152 |
003 |
DE-627 |
005 |
20230425182118.0 |
007 |
cr uuu---uuuuu |
008 |
210507s2023 xx |||||o 00| ||dut c |
035 |
|
|
|a (DE-627)WHO006497152
|
035 |
|
|
|a (UBBS_Klinische_Studien_WHO)NTR6327
|
035 |
|
|
|a (UBBS_Klinische_Studien_WHO)NL5961
|
035 |
|
|
|a (UBBS_Klinische_Studien_WHO)NL57812.042.16
|
040 |
|
|
|a DE-627
|b ger
|c DE-627
|e rakwb
|
041 |
|
|
|a dut
|
245 |
1 |
0 |
|a Hoe is de opname van voeding bij mensen die een HIPEC ondergaan?
|b Predictive factors for sarcopenia and malabsorption in high risk surgical oncological patients after cytoreductive surgery and HIPEC procedure
|
264 |
|
1 |
|c 2023
|
336 |
|
|
|a Text
|b txt
|2 rdacontent
|
337 |
|
|
|a Computermedien
|b c
|2 rdamedia
|
338 |
|
|
|a Online-Ressource
|b cr
|2 rdacarrier
|
500 |
|
|
|a WHO International Clinical Trials Registry Platform (https://www.who.int/ictrp/en/), First posted: 2017-01-11, Last updated: 2023-04-06
|
650 |
|
4 |
|a Medical Condition: Patients diagnosed with abdominal cancer and treated with cytoreductive surgery (CRS) and a hyperthermic intraperitoneal chemotherapy (HIPEC) procedure
|
650 |
|
4 |
|a Study Type: Observational non invasive
|
650 |
|
4 |
|a Recruitment Status: Recruiting
|
650 |
|
4 |
|a 610
|
773 |
0 |
8 |
|i Enthalten in
|t WHO International Clinical Trials Registry Platform
|g (2023) vom: 03. Apr.
|
773 |
1 |
8 |
|g year:2023
|g day:03
|g month:04
|
856 |
4 |
0 |
|u https://www.onderzoekmetmensen.nl/en/trial/28190
|z kostenfrei
|3 Volltext
|
912 |
|
|
|a GBV_CTG
|
912 |
|
|
|a SSG-OLC-PHA
|
951 |
|
|
|a AR
|
952 |
|
|
|j 2023
|b 03
|c 04
|